Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous vs Cyclic COC Use
NCT00570440Phase 4Completed
- Sponsor
- FHI 360
- Start
- Aug 2007
- Primary completion
- Oct 2010
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of ethinylestradiol + levonorgestrel in contraception (2 arms), sponsored by FHI 360. Primary endpoint: 12 month cumulative COC discontinuation probabilities. Started Aug 2007; status: completed.
02
Drugs
ethinylestradiol + levonorgestrel
03
Conditions
contraception
Beyond the preview
Go deeper on NCT00570440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00570440.